COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression Post published:June 28, 2021 Post category:Press Release
Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And AWKN002, Two Next- Generation New Chemical Entities [NCEs] To Treat A Broad Range Of Addiction Indications Post published:June 28, 2021 Post category:Press Release
MindMed Included in FTSE Russell 3000® Index Post published:June 28, 2021 Post category:Press Release
UK Set to Become Hub of Psychedelic Research, as British Startup Gears-up to Run Trials for International Psychedelic Drug Developers Post published:June 25, 2021 Post category:Press Release
Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results Post published:June 24, 2021 Post category:Press Release
Wesana Health Partners with University of South Carolina Post published:June 24, 2021 Post category:Press Release
Albert Labs Announces a Distinguished Clinical and Scientific Advisory Board Post published:June 24, 2021 Post category:Press Release
Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt as Chief Research Officer Post published:June 24, 2021 Post category:Press Release
Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board Post published:June 24, 2021 Post category:Press Release
Exclusively-Natural Psychedelic Pharma Company, Filament Health, Lists on the NEO Exchange Post published:June 24, 2021 Post category:Press Release